BIOMAT Database Logo BIOMAT Database Logo

Once-daily saquinavir-hgc plus low-dose ritonavir (1200/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy. 2003

Luis F López-Cortés, and Rosa Ruiz-Valderas, and Rosario Pascual, and Magdalena Rodriguez, and Ana Marín Niebla

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D018445 Infectious Disease Transmission, Vertical The transmission of infectious disease or pathogens from one generation to another. It includes transmission in utero or intrapartum by exposure to blood and secretions, and postpartum exposure via breastfeeding. Fetomaternal Infection Transmission,Infection Transmission, Fetomaternal,Infection Transmission, Maternal-Fetal,Infection Transmission, Vertical,Maternal-Fetal Infection Transmission,Mother-to-Child Transmission,Pathogen Transmission, Vertical,Vertical Infection Transmission,Vertical Infectious Disease Transmission,Vertical Transmission of Infectious Disease,Infection Transmission, Maternal Fetal,Maternal Fetal Infection Transmission,Mother to Child Transmission,Mother-to-Child Transmissions,Transmission, Fetomaternal Infection,Transmission, Maternal-Fetal Infection,Transmission, Mother-to-Child,Transmission, Vertical Infection,Transmission, Vertical Pathogen,Transmissions, Mother-to-Child,Vertical Pathogen Transmission
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts
D019258 Saquinavir An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A. Invirase,Ro 31-8959,Saquinavir Mesylate,Saquinavir Monomethanesulfonate,Saquinivir,Monomethanesulfonate, Saquinavir,Ro 31 8959,Ro 318959

Related Publications

Luis F López-Cortés, and Rosa Ruiz-Valderas, and Rosario Pascual, and Magdalena Rodriguez, and Ana Marín Niebla
Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
January 2015, Antiviral therapy,
Luis F López-Cortés, and Rosa Ruiz-Valderas, and Rosario Pascual, and Magdalena Rodriguez, and Ana Marín Niebla
Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women.
February 2004, Antimicrobial agents and chemotherapy,
Luis F López-Cortés, and Rosa Ruiz-Valderas, and Rosario Pascual, and Magdalena Rodriguez, and Ana Marín Niebla
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.
April 2005, The Journal of antimicrobial chemotherapy,
Luis F López-Cortés, and Rosa Ruiz-Valderas, and Rosario Pascual, and Magdalena Rodriguez, and Ana Marín Niebla
Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.
October 2016, HIV medicine,
Luis F López-Cortés, and Rosa Ruiz-Valderas, and Rosario Pascual, and Magdalena Rodriguez, and Ana Marín Niebla
Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.
October 2004, The Journal of antimicrobial chemotherapy,
Luis F López-Cortés, and Rosa Ruiz-Valderas, and Rosario Pascual, and Magdalena Rodriguez, and Ana Marín Niebla
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
November 2006, The Journal of antimicrobial chemotherapy,
Luis F López-Cortés, and Rosa Ruiz-Valderas, and Rosario Pascual, and Magdalena Rodriguez, and Ana Marín Niebla
Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women.
December 2011, Therapeutic drug monitoring,
Luis F López-Cortés, and Rosa Ruiz-Valderas, and Rosario Pascual, and Magdalena Rodriguez, and Ana Marín Niebla
Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients.
May 2006, MedGenMed : Medscape general medicine,
Luis F López-Cortés, and Rosa Ruiz-Valderas, and Rosario Pascual, and Magdalena Rodriguez, and Ana Marín Niebla
Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy.
April 2007, Therapeutic drug monitoring,
Luis F López-Cortés, and Rosa Ruiz-Valderas, and Rosario Pascual, and Magdalena Rodriguez, and Ana Marín Niebla
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients.
September 2014, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!